loading…
Q0224 Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg
BackQ0035Cardiokymography→Q0081Infusion therapy, using other than chemotherapeutic drugs, per visit→Q0083Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit→Q0084Chemotherapy administration by infusion technique only, per visit→Q0085Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit→Q0091Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory→Q0092Set-up portable x-ray equipment→Q0111Wet mounts, including preparations of vaginal, cervical or skin specimens→Q0112All potassium hydroxide (koh) preparations→Q0113Pinworm examinations→Q0114Fern test→Q0115Post-coital direct, qualitative examinations of vaginal or cervical mucous→Q0138Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)→Q0139Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)→Q0144Azithromycin dihydrate, oral, capsules/powder, 1 gram→Q0155Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen→Q0161Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen→Q0162Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen→Q0163Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen→Q0164Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen→Q0166Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen→Q0167Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen→Q0169Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen→Q0173Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen→Q0175Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen→Q0177Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen→Q0180Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen→Q0181Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen→Q0224Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg→Q0234Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg→Q0235Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg→Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg→Q0238Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg→Q0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg→Q0477Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0478Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type→Q0479Power module for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0480Driver for use with pneumatic ventricular assist device, replacement only→Q0481Microprocessor control unit for use with electric ventricular assist device, replacement only→Q0482Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only→Q0483Monitor/display module for use with electric ventricular assist device, replacement only→Q0484Monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0485Monitor control cable for use with electric ventricular assist device, replacement only→Q0486Monitor control cable for use with electric/pneumatic ventricular assist device, replacement only→Q0487Leads (pneumatic/electrical) for use with any type electric/pneumatic ventricular assist device, replacement only→Q0488Power pack base for use with electric ventricular assist device, replacement only→Q0489Power pack base for use with electric/pneumatic ventricular assist device, replacement only→Q0490Emergency power source for use with electric ventricular assist device, replacement only→Q0491Emergency power source for use with electric/pneumatic ventricular assist device, replacement only→Q0492Emergency power supply cable for use with electric ventricular assist device, replacement only→Q0493Emergency power supply cable for use with electric/pneumatic ventricular assist device, replacement only→Q0494Emergency hand pump for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0495Battery/power pack charger for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0496Battery, other than lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0497Battery clips for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0498Holster for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0499Belt/vest/bag for use to carry external peripheral components of any type ventricular assist device, replacement only→Q0500Filters for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0501Shower cover for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0502Mobility cart for pneumatic ventricular assist device, replacement only→Q0503Battery for pneumatic ventricular assist device, replacement only, each→Q0504Power adapter for pneumatic ventricular assist device, replacement only, vehicle type→Q0506Battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only→Q0507Miscellaneous supply or accessory for use with an external ventricular assist device→Q0508Miscellaneous supply or accessory for use with an implanted ventricular assist device→Q0509Miscellaneous supply or accessory for use with any implanted ventricular assist device for which payment was not made under medicare part a→Q0510Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant→Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period→Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period→Q0513Pharmacy dispensing fee for inhalation drug(s); per 30 days→Q0514Pharmacy dispensing fee for inhalation drug(s); per 90 days→Q0515Injection, sermorelin acetate, 1 microgram→Q0521Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription→
Procedure codeCODABLE
Q0224
Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg
- Part
- HCPCS Level II
- Q
- Temporary Codes
- Q0
- Q0035–Q0521
Source
CMS — ICD-10-PCS FY2026, HCPCS Level II october 2026, Procedure Codes 2026.